AstraZeneca pauses Covid-19 vaccine trial after unexplained illness
Pharmaceutical company says it has"voluntarily paused" a randomised clinical trial of its coronavirus vaccine, in what it called a routine action after a volunteer developed an unexplained illness.
Pharmaceutical company AstraZeneca said Tuesday it had "voluntarily paused" a randomised clinical trial of its coronavirus vaccine, in what it called a routine action after a volunteer developed an unexplained illness.
The company, which is developing the drug alongside the University of Oxford, is a frontrunner in the global race for a Covid-19 vaccine. Argentina's government has signed up to co-produce hundreds of millions of doses of the vaccine with Mexico, for use in Latin America, when it passes clinical trials.
"As part of the ongoing randomised, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," a spokesperson said.
"This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials."
It added that in large trials, illnesses will sometimes happen by chance but must be reviewed independently.
"We are working to expedite the review of the single event to minimise any potential impact on the trial timeline," the spokesperson added.
It was not immediately clear where the patient was, or the nature and severity of their illness.
Holds during clinical trials are not uncommon, but this is thought to be the first time it has happened for a Covid-19 vaccine trial.
AstraZeneca is one of nine companies currently in late-stage Phase 3 trials for their vaccine candidates.
In the US, the company began enrolling 30,000 volunteers across dozens of sites on August 31.
The vaccine, called AZD1222, uses a weakened version of a common cold causing adenovirus that has been engineered to code for the spike protein that the novel coronavirus uses to invade cells.
After vaccination, this protein is produced inside the human body, which primes the immune system to attack the coronavirus if the person is later infected.
– TIMESAFP
related news
-
'A mistake': Spanish minister backtracks on Milei 'substances' remark
-
Argentina reinforces desire to deepen ties with 'natural partner' EU
-
Far-right surge in European elections may put EU-CELAC relations at risk
-
Milei admits Malvinas Islands are ‘in the hands of the UK’
-
Spain slams Milei's claim that PM Sánchez is delivering 'poverty and death'
-
Foreign Minister Diana Mondino says 'Chinese people are the same'
-
Media watchdog says press freedom has deteriorated under Milei
-
EU-Mercosur deal is ‘win-win,’ says Poland’s ambassador to Argentina
-
Argentina given roadmap for OECD ascension
-
Horacio Méndez Carreras upheld dignity and decency in inglorious times